Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00389610
NCT00389610CompletedPhase 2

A Safety and Efficacy Trial of Vaccine Boosting With Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected With the GM-CSF Gene for the Treatment of Pancreatic Adenocarcinoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins2 sites in 1 country56 target enrollmentStarted: September 11, 2006Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
56
Locations
2
Primary Endpoint
Number of Patients Experiencing a Grade 3 or Above Treatment- Related Toxicity
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This is an open label, phase II trial study of adjuvant GVAX pancreas vaccine in patients with pancreatic cancer.

Detailed Description

Eligible participants will receive by intradermal administration the GVAX pancreas vaccine consisting of two irradiated allogeneic pancreatic tumor cell lines transfected with the granulocyte macrophage-colony stimulating factor (GM-CSF) gene.

There will be two cohorts of research participants:

  1. Participants previously vaccinated with GVAX pancreas vaccine. These participants will receive booster vaccinations as a continuation of care. Vaccination repeats every 6 months in the absence of disease progression or unacceptable toxicity.
  2. Participants who were not previously vaccinated with GVAX pancreas vaccine (vaccine naive). These participants received priming vaccinations once a month for 3 months followed by booster vaccinations every 6 months.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •A. previously vaccinated subjects must receive Gvax vaccine previously
  • •B. naïve and previously vaccinated subjects must meet the following criteria:
  • •have a history of surgically resected pathologic stage 1,2 or 3 adenocarcinoma of the head, neck, tail, or uncinate of the pancreas
  • •received the last anti-cancer therapy at least 28 days ago.
  • •provide informed consent.
  • •have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
  • •have adequate hematologic function (Hemoglobin ≥ 9 gm/dl, Absolute neutrophil count (ANC) ≥ 1500 #/cu mm, platelets ≥100,000 K/cu mm)
  • •have adequate renal function (Serum creatinine ≤ 2 mg/dL).
  • •have adequate hepatic function (Bilirubin ≤ 2.0 mg/dL, unless known Gilbert's Syndrome; Aspartate Aminotransferase (AST), Alanine transaminase (ALT) and amylase ≤ 2x upper limit of normal: Alk Phosphatase ≤ 5x upper limit of normal.)
  • •agree to use adequate birth control, if of childbearing potential.
  • •Exclusion criteria:
  • •radiographical evidence of pancreatic cancer disease recurrence
  • •documented history of autoimmune diseases including systemic lupus erythematosus, sarcoidosis, rheumatoid arthritis, glomerulonephritis, or vasculitis
  • •uncontrolled medical problems
  • •systemic steroid therapy within 28 days before vaccine administration
  • •anticipated need for systemic steroid therapy within 28 days after vaccine administration
  • •evidence of active infections

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Number of Patients Experiencing a Grade 3 or Above Treatment- Related Toxicity

Time Frame: 14 years

When calculating the incidences of adverse events, each adverse event (as defined by NCI CTCAE v3) will be counted only once for a given subject.

Secondary Outcomes

  • Disease-free Survival (DFS)(16 years)
  • Overall Survival (OS)(16 years)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials

Completed
Phase 2
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic CancerMetastatic Pancreatic Cancer
NCT01417000Aduro Biotech, Inc.93
Completed
Phase 2
Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer
NCT02004262Aduro Biotech, Inc.303
Completed
Phase 2
GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic CancerPancreatic Cancer
NCT03161379Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins31
Completed
Early Phase 1
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the PancreasPancreatic Cancer
NCT03153410Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins11
Completed
Phase 2
Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)Vulvar DysplasiaVulvar Intraepithelial Neoplasia (VIN)VIN2VIN3Pre-cancerous Lesions of the VulvaHuman Papillomavirus (HPV)
NCT03180684Inovio Pharmaceuticals33